Therapeutic strategies for congenital myasthenic syndromes
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS...
| Autors principals: | , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
Wiley
2018
|